Currently out of the existing stock ratings of Robert Burns, 316 are a BUY (88.02%), 43 are a HOLD (11.98%).

Robert Burns

Work Performance Price Targets & Ratings Chart

Analyst Robert Burns, currently employed carries an average stock price target met ratio of 23.51% that have a potential upside of 41.03% achieved within 91 days. Previously, Robert Burns worked at HC WAINWRIGHT.

Robert Burns’s has documented 740 price targets and ratings displayed on 38 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on YMAB, Y mAbs Therapeutics at 15-Nov-2024.

Wall Street Analyst Robert Burns

Analyst best performing recommendations are on PRLD (PRELUDE THERAPEUTICS ).
The best stock recommendation documented was for PRLD (PRELUDE THERAPEUTICS ) at 9/10/2024. The price target of $5 was fulfilled within 1 day with a profit of $0.38 (7.06%) receiving and performance score of 70.63.

Average potential price target upside

AADI Aadi Bioscience BNTX BioNTech SE CRBU Caribou Biosciences CTMX CytomX Therapeutics FATE Fate Therapeutics IGMS IGM Biosciences MGNX MacroGenics NRIX Nurix Therapeutics  NUVB Nuvation Bio ORIC Oric Pharmaceuticals  RLAY Relay Therapeutics  RPTX Repare Therapeutics RVMD Revolution Medicines ADCT ADC Therapeutics SA IKNA Ikena Oncology KRON Kronos Bio  NCNA NuCana PLC PRTG Portage Biotech TCRR Tcr2 Therapeutics TPTX Turning Point Therapeutics ZYME Zymeworks . Common Stock SWTX SpringWorks Therapeutics NLTX Neoleukin Therapeutics PRLD Prelude Therapeutics  YMAB Y mAbs Therapeutics ATRA Atara Biotherapeutics GTBP GT Biopharma KNTE Kinnate Biopharma  OMGA Omega Therapeutics PMVP Pmv Pharmaceuticals  REPL Replimune Group TNGX Tango Therapeutics ALLO Allogene Therapeutics BDTX Black Diamond Therapeutics COGT Cogent Biosciences VIRX Viracta Therapeutics AUTL Autolus Therapeutics Ltd FMTX Forma Therapeutics Holdings

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$1.75

$-0.32 (-15.46%)

$5

2 months 25 days ago
(27-Aug-2024)

1/6 (16.67%)

$0.07 (4.17%)

2

Hold

3 months ago
(21-Aug-2024)

0/4 (0%)

$31.56 (191.97%)

Buy

$1.5

$-0.57 (-27.54%)

3 months ago
(21-Aug-2024)

0/2 (0%)

$-0.05 (-3.23%)

Buy

2 years 7 months 10 days ago
(11-Apr-2022)

0/1 (0%)

$93 (163.16%)

Buy

2 years 7 months 10 days ago
(11-Apr-2022)

2/2 (100%)

$4.5 (25.00%)

82

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Robert Burns is most bullish on?

Potential upside of $50.28 has been obtained for BNTX (BIONTECH SE)

Which stock is Robert Burns is most reserved on?

Potential downside of -$3.39 has been obtained for ZYME (ZYMEWORKS . COMMON STOCK)

What Year was the first public recommendation made by Robert Burns?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?